TB-500
Thymosin Beta-4 is one of nature's most ubiquitous peptides, found in virtually every mammalian cell at high concentrations. This 43-amino acid sequence plays a critical role in actin regulation and tissue repair.
22 min read · Last updated March 2026 · 25+ research citations
Research Use Only: TB-500/Thymosin Beta-4 is not approved by the FDA for human therapeutic use. It is prohibited by WADA for athletic competition. All information is based on preclinical research for educational purposes only.
Key Takeaways
Overview
What is TB-500?
Thymosin Beta-4 (Tb4) is one of nature's most ubiquitous and conserved peptides. First isolated from thymus tissue in 1981 by Allan Goldstein and colleagues at George Washington University, this 43-amino acid peptide has since been identified in virtually every mammalian cell type. Unlike many signaling peptides present in trace amounts, Tb4 exists at remarkably high intracellular concentrations - typically 100-500 microM - making it one of the most abundant peptides in the body.
Molecular Characteristics
Full Amino Acid Sequence
Why is Tb4 So Abundant?
The extraordinary intracellular concentration of Thymosin Beta-4 reflects its critical role in actin dynamics. Actin is one of the most abundant proteins in eukaryotic cells, and its constant assembly and disassembly drive essential processes including cell movement, division, and shape maintenance.
Tb4 serves as the primary "buffer" for actin monomers, maintaining a reservoir of building blocks ready for rapid mobilization when needed.
Natural Functions
Historical Discovery and Development
Clarification
TB-500 vs Thymosin Beta-4: Understanding the Difference
One of the most common sources of confusion in peptide research involves the relationship between TB-500 and Thymosin Beta-4. While often used interchangeably, they are not identical compounds.
Understanding the Terminology
| Characteristic | Thymosin Beta-4 (Tb4) | TB-500 |
|---|---|---|
| Amino Acid Length | 43 (full native sequence) | 17-44 (varies by formulation) |
| Origin | Full native sequence | Synthetic fragment or analog |
| Active Regions | Contains both Ac-SDKP + LKKTET | Typically contains LKKTET motif |
| Research Use | Mechanistic and clinical studies | Applied research, general market |
| Synthesis | Complex, more expensive | Simplified, cost-effective |
| Clinical Development | RGN-259 (RegeneRx) | Not in clinical trials |
N-Terminal Ac-SDKP Tetrapeptide (aa 1-4)
The acetylated N-terminal sequence Ac-SDKP has independent biological activity:
- Released naturally from Tb4 by prolyl oligopeptidase
- Anti-fibrotic properties documented in multiple organ systems
- Anti-inflammatory effects through macrophage modulation
- Protected from degradation by ACE inhibitors
Central LKKTET Actin-Binding Motif (aa 17-22)
The hexapeptide LKKTET is the primary actin-binding sequence:
- Essential for G-actin interaction
- Responsible for actin sequestration activity
- Preserved in most TB-500 formulations
- Sufficient for many regenerative effects in research models
What Exactly is TB-500?
The term "TB-500" lacks a single standardized definition. In practice, TB-500 products may be:
This variability means TB-500 products from different sources may differ in composition, potentially affecting research reproducibility. For clinical research purposes, full-length Thymosin Beta-4 (as in RGN-259) represents the standardized compound.
Science
How TB-500 Works
The mechanism of action of Thymosin Beta-4 is unusually well-characterized compared to many research peptides
Primary Mechanism: Actin Sequestration
The fundamental function of Tb4 is regulation of the actin cytoskeleton through G-actin sequestration.
The Actin Dynamics System
Cells maintain dynamic pools of actin in two forms:
- G-actin (Globular):Monomeric, soluble actin subunits
- F-actin (Filamentous):Polymerized actin filaments forming the cytoskeleton
Tb4 Binding Properties
Tb4 binds G-actin with 1:1 stoichiometry and moderate affinity (Kd approximately 2 microM). This binding:
- • Prevents spontaneous actin polymerization
- • Creates a reservoir of actin monomers
- • Enables rapid cytoskeleton reorganization
- • Supports wound healing processes
Structural Basis: Intrinsically Disordered Protein (IDP)
Thymosin Beta-4 is classified as an IDP, meaning it lacks stable secondary structure in isolation. This apparent "disorder" is functionally critical:
Secondary Mechanisms
Anti-inflammatory Pathways
- M1 to M2 macrophage shift
- Reduced TNF-alpha, IL-1beta
- Inhibits inflammatory cell recruitment
- NF-kappaB suppression
Angiogenesis Promotion
- Enhanced endothelial cell migration
- Increased capillary density
- VEGF upregulation
- HIF-1alpha pathway activation
Cell Survival Pathways
- Akt pathway activation
- ILK (Integrin-Linked Kinase) activation
- Anti-apoptotic effects
- Hypoxia protection
ECM Interactions
- Collagen organization effects
- MMP modulation
- Fibroblast function influence
- Reduced scarring
Evidence
Research Overview
Thymosin Beta-4 has been studied extensively across multiple tissue systems
Wound Healing Research
Most StudiedThe foundational wound healing studies were published by Malinda and colleagues in 1999 in the Journal of Investigative Dermatology.
Cardiac Research
2 Nature Publications"Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair"
"Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization"
RegeneRx Biopharmaceuticals pursued cardiac applications with mixed results. Phase 2 trials in acute MI patients did not meet primary endpoints. Cardiac development deprioritized in favor of ophthalmological applications.
Corneal Healing Research
Phase 2/3 TrialsCorneal applications represent the most advanced clinical development of Thymosin Beta-4, with RGN-259 progressing through Phase 2 and Phase 3 clinical trials.
Tendon & Muscle Research
Neurological Research
Comparison
TB-500 vs BPC-157: Detailed Comparison
Quick Comparison
| Property | TB-500 / Thymosin Beta-4 | BPC-157 |
|---|---|---|
| Full Name | Thymosin Beta-4 Fragment | Body Protection Compound-157 |
| Amino Acids | 43 (full) / varies (fragment) | 15 |
| Molecular Weight | 4,963 Da (full Tb4) | 1,419 Da |
| Origin | Thymus-derived, ubiquitous in cells | Gastric juice derivative |
| Natural Abundance | High (100-500 microM cellular) | Low (trace in gastric juice) |
| Primary Mechanism | Actin sequestration | NO system, growth factors |
| Mechanism Clarity | Well-defined (actin binding) | Multiple proposed pathways |
| Research Focus | Cardiac, wound, corneal | GI, tendon, musculoskeletal |
| Clinical Trials | Phase 2/3 (RGN-259, ocular) | None significant |
| Oral Stability | Not orally active | Acid-stable |
| WADA Status | Prohibited | Not listed (monitored) |
TB-500/Tb4 Strengths
- Extensive research volume from multiple institutions
- Primary mechanism well-defined (actin binding)
- Phase 2/3 clinical trial progress (ocular)
- Two Nature publications on cardiac effects
- Better independent replication across labs
BPC-157 Strengths
- Oral bioavailability (acid-stable)
- Extensive GI research applications
- Budget-friendly for preliminary studies
- Not explicitly WADA prohibited
- More tendon research with oral route
Complementary vs. Redundant?
Rather than being redundant, TB-500 and BPC-157 appear to operate through largely distinct mechanisms:
BPC-157 TB-500/Tb4
──────── ──────────
NO System ←────────────────────→ Actin Sequestration
↓ ↓
Growth Factors ←───────────────→ Cell Migration
↓ ↓
Angiogenesis ←──── OVERLAP ────→ Angiogenesis
↓ ↓
Tissue Repair ←─── OVERLAP ────→ Wound HealingThe overlap in endpoints (angiogenesis, tissue repair) despite different mechanisms forms the theoretical basis for combination approaches.
Combination Protocol
The Wolverine Stack: TB-500 + BPC-157
The combination of TB-500 and BPC-157, colloquially termed the "Wolverine Stack," has gained attention in peptide research circles. Named for the fictional Marvel character with exceptional regenerative abilities, this combination is based on theoretical mechanistic complementarity.
Theoretical Rationale
Evidence Base: Critical Assessment
- Individual peptides have documented effects in preclinical models
- Mechanisms are distinct and potentially complementary
- No pharmacokinetic interference would be expected
- No published studies comparing the combination
- No controlled trials evaluating synergy
- No safety data for concurrent administration
- No pharmacokinetic interaction studies
Critical Caveat: The Wolverine Stack remains a theoretical concept. Claims of synergy are extrapolations from individual peptide data, not empirical findings from combination studies.
Protocols
Dosage Information
Important: The following dosage information is compiled from preclinical research literature. These are NOT clinical recommendations and human therapeutic dosing has not been established.
Animal Study Dosages
| Application | Model | Dose Range | Route | Duration |
|---|---|---|---|---|
| Wound Healing | Rodent | 0.1-5 mcg/application | Topical | Daily |
| Cardiac | Mouse | 0.1-6 mg/kg | IP/IV | Variable |
| Corneal | Rodent/Human | 0.1% solution | Topical (eye) | BID-QID |
| Systemic | Rodent | 0.5-6 mg/kg | SC/IP | Daily-weekly |
| In Vitro | Cell culture | 1-100 ng/mL | Media | Variable |
Commonly Cited Human-Equivalent Estimates
Important Disclaimer: These are estimates based on allometric scaling from animal data and do NOT represent clinically validated doses.
Clinical Trial Dosing (RGN-259)
The most robust dosing data comes from clinical trials of RGN-259 for ophthalmological applications:
Methods
Administration Routes
Subcutaneous
Most Common Research Route
- Simple technique
- Consistent absorption
- Systemic distribution
Intramuscular
Into muscle tissue
- Similar to subcutaneous
- Larger volume capacity
- Some musculoskeletal studies
Intravenous
Direct bloodstream
- Immediate, complete bioavailability
- Rapid onset
- Acute cardiac studies
Intraperitoneal
Into abdominal cavity
- Common in rodent studies
- Relatively rapid absorption
- Research technique
Topical
Direct application
- RGN-259 eye drops
- Local concentration
- Minimal systemic exposure
Local Injection
Near injury site
- High local concentration
- Lower total dose
- Tendon/tissue studies
Reconstitution and Storage
Reconstitution Steps
- Allow vial to reach room temperature (10-15 minutes)
- Add sterile water or bacteriostatic water slowly along vial wall
- Swirl gently - do not vortex or shake vigorously
- Allow complete dissolution before use
- Prepare aliquots to minimize freeze-thaw cycles
- Document reconstitution date and concentration
Storage Recommendations
Note: Tb4 contains methionine (oxidation-sensitive). Minimize oxygen exposure.
Safety
Side Effects & Safety Profile
Research Findings
Good tolerability in published research with minimal adverse effects reported
No serious adverse events attributed to treatment. Local effects consistent with eye drop administration.
Low in preclinical models. No lethal dose established.
Cancer & Tumor Growth Concerns
Tb4 promotes cell migration and angiogenesis - processes also utilized by tumors.
- • No evidence Tb4 causes cancer (tumor initiation)
- • Effects on existing tumors are complex/context-dependent
- • No increased cancer in RGN-259 trials
Expert Consensus: Current evidence does not support Tb4 as a tumor initiator. However, caution warranted in individuals with existing malignancies.
Populations Requiring Caution
Legal
Regulatory Status
FDA Status
Not Approved for Human Therapeutic Use
- • No approved NDA
- • Investigational use only
- • RGN-259 represents potential pathway
WADA Status
Prohibited in Sport
- • Listed under S2: Peptide Hormones
- • Prohibited in & out of competition
- • Testing methods available
- • Violations = significant sanctions
DEA Status
Not a Controlled Substance
- • No scheduling under CSA
- • Legal to possess for research
- • Not approved for human use
Quality and Sourcing Concerns
Without pharmaceutical regulation, research-grade TB-500 faces quality challenges:
- • Purity variation between suppliers
- • Sequence verification often lacking
- • Potential contamination issues
- • Stability during shipping uncertain
- • Request Certificate of Analysis (CoA)
- • Verify HPLC purity (>98%)
- • Confirm mass spectrometry data
- • Request endotoxin testing for in vivo use
FAQ
Frequently Asked Questions
Critical Analysis
Current Research Limitations
Translation Challenges
Most data from rodent models. Cardiac trial disappointments illustrate human translation challenges.
Dose Extrapolation
Allometric scaling provides estimates only. Human-equivalent dosing not clinically validated.
Product Heterogeneity
Variable TB-500 formulations across studies. Different dosing protocols and endpoints.
Limited Human Data
RGN-259 provides best clinical evidence (topical ocular). Systemic administration data minimal.
Failed Translation
Cardiac trials did not meet primary endpoints. Animal models may overestimate human efficacy.
Long-term Safety
Most studies short-term. Chronic effects poorly characterized. Cancer concerns need monitoring.
Current Status Summary
| Aspect | Evidence Level | Notes |
|---|---|---|
| Actin-binding mechanism | Strong | Well-characterized biochemically |
| Wound healing (animal) | Moderate-Strong | Multiple studies, consistent findings |
| Cardiac effects (animal) | Strong | Nature publications, mechanistic detail |
| Cardiac effects (human) | Weak | Clinical trials disappointing |
| Corneal healing (human) | Moderate | Phase 2/3 trial data supportive |
| Systemic safety (long-term) | Insufficient | Limited data available |
| Cancer effects | Insufficient | Theoretical concerns, limited data |
References
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032.
- Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472.
- Smart N, Risebro CA, Melville AAD, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
- Sosne G, Qiu P, Goldstein AL, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151.
- Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115.
- Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299.
- Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. 2008;117(17):2232-2240.
- Morris DC, Chopp M, Zhang L, et al. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682.
- Xiong Y, Mahmood A, Meng Y, et al. Treatment of traumatic brain injury with thymosin beta4 in rats. J Neurosurg. 2011;114(1):102-115.
- Sosne G, Qiu P, Christopherson PL, et al. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-669.
- Reti R, Kwon E, Qiu P, et al. Thymosin beta4 is cytoprotective in human gingival fibroblasts. Eur J Oral Sci. 2008;116(5):424-430.
- Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2007;1112:385-395.
- Huff T, Muller CS, Otto AM, et al. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220.
- Kleinman HK, Sosne G. Thymosin beta4 promotes dermal healing. Vitam Horm. 2016;102:251-275.
- Ehrlich HP, Bhardwaj N. Thymosin beta 4 is not unique to wound repair. Wound Repair Regen. 2012;20(4):469.
- Sosne G, Siddiqi A, Kurpakus-Wheater M. Thymosin-beta4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro. Invest Ophthalmol Vis Sci. 2004;45(4):1095-1100.
- Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin beta4. Expert Opin Biol Ther. 2015;15(Suppl 1):S139-S145.
- Philp D, Kleinman HK. Animal studies with thymosin beta4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial. Clin Ophthalmol. 2015;9:877-884.
- Dunn SP, Heidemann DG, Chow CY, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Ann N Y Acad Sci. 2010;1194:199-206.
- Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4. Proc Natl Acad Sci U S A. 1981;78(2):1162-1166.
- Peng H, Xu J, Yang XP, et al. Thymosin-beta4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2014;307(5):H741-H751.
- Wei C, Kumar S, Kim IK, Bhaumik S, et al. Thymosin beta 4 protects cardiomyocytes from oxidative stress. PLoS One. 2012;7(8):e42586.
Disclaimer: This pillar page is intended for educational and research purposes only. TB-500/Thymosin Beta-4 is a research compound that has not been approved by the FDA for human use and is prohibited by WADA for athletic competition. Nothing in this document should be construed as medical advice or a recommendation for use. Always consult with qualified professionals and follow all applicable laws and regulations.
Last updated: March 2026 · Reviewed by: Scientific Aminos Editorial Board
Order TB-500 Wholesale
US-manufactured, HPLC verified. Available for distributors, telehealth providers, clinics, and research institutions.